Irene Bultink

List of Publications by Citations

Source: https://exaly.com/author-pdf/5000955/irene-bultink-publications-by-citations.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

1,521
citations

h-index

38
g-index

54
ext. papers

1,838
ext. citations

4.4
avg, IF

L-index

#	Paper	IF	Citations
48	Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2044-50		191
47	Advances in glucocorticoid-induced osteoporosis. Current Rheumatology Reports, 2011, 13, 233-40	4.9	119
46	Sensing of latent EBV infection through exosomal transfer of 5MppRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E587-96	11.5	99
45	Osteoporosis and fractures in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012 , 64, 2-8	4.7	87
44	Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. <i>Rheumatology</i> , 2017 , 56, 121-128	3.9	80
43	Inflammatory rheumatic disorders and bone. Current Rheumatology Reports, 2012, 14, 224-30	4.9	68
42	Optimizing fracture prevention: the fracture liaison service, an observational study. <i>Osteoporosis International</i> , 2014 , 25, 701-9	5.3	58
41	Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. <i>Osteoporosis International</i> , 2013 , 24, 1827-33	5.3	53
40	Management of osteoporosis in rheumatoid arthritis patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 559-71	4	48
39	Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. <i>Osteoporosis International</i> , 2014 , 25, 1275-83	5.3	46
38	Osteoarthritis and osteoporosis: what is the overlap?. Current Rheumatology Reports, 2013, 15, 328	4.9	44
37	Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. <i>Rheumatology</i> , 2016 , 55, 939-48	3.9	42
36	Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 185-97	4	40
35	Glucocorticoids, Inflammation and Bone. Calcified Tissue International, 2018, 102, 592-606	3.9	38
34	Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2008 , 26, 32-8	2.2	38
33	Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 389-90	2.4	37
32	Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 290-301	9.5	36

(2017-2016)

31	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016 , 3, e000163	4.6	34
30	Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006 , 8, R183	5.7	32
29	Lupus and fractures. Current Opinion in Rheumatology, 2016 , 28, 426-32	5.3	32
28	High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. <i>Journal of Rheumatology</i> , 2008 , 35, 1053-7	4.1	32
27	Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus. <i>Calcified Tissue International</i> , 2018 , 102, 575-591	3.9	25
26	Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. <i>Drugs</i> , 2019 , 79, 1065-1087	12.1	21
25	Physiological evidence for diversification of IFNE and IFNE mediated response programs in different autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2016 , 18, 49	5.7	21
24	Systemic lupus erythematosus and fractures. <i>RMD Open</i> , 2015 , 1, e000069	5.9	19
23	Making the invisible visible: bioelectrical impedance analysis demonstrates unfavourable body composition in rheumatoid arthritis patients in clinical practice. <i>Scandinavian Journal of Rheumatology</i> , 2014 , 43, 273-8	1.9	18
22	Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. <i>Scandinavian Journal of Immunology</i> , 2016 , 84, 100-9	3.4	18
21	The relationship between remission and health-related quality of life in a cohort of SLE patients. <i>Rheumatology</i> , 2019 , 58, 628-635	3.9	18
20	Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes. <i>Journal of Immunology</i> , 2017 , 198, 82-93	5.3	16
19	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. <i>Rheumatology</i> , 2021 , 60, 207-216	3.9	15
18	Systemic lupus erythematosus: review of synthetic drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2793-806	4	14
17	Prevalence of malnutrition and validation of bioelectrical impedance analysis for the assessment of body composition in patients with systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, 1008-1012	3.9	12
16	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017 , 56, 1586-1596	3.9	10
15	Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 95-100	2.2	10
14	Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study. <i>Journal of Immunology Research</i> , 2017 , 2017, 8245879	4.5	8

13	Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study. <i>Hypertension in Pregnancy</i> , 2017 , 36, 8-15	2	8
12	Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity. <i>Molecular Immunology</i> , 2017 , 92, 125-131	4.3	6
11	FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE. <i>European Journal of Immunology</i> , 2016 , 46, 762-71	6.1	6
10	Management of glucocorticoid-induced osteoporosis. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 793-804	4.8	4
9	Unexpected severe incident vertebral fractures in patients with systemic lupus erythematosus: comment on the article by Zhu et al. <i>Lupus</i> , 2015 , 24, 222-3	2.6	3
8	Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. <i>Rheumatology</i> , 2021 , 60, 5134-5141	3.9	2
7	The association between FOK-I vitamin D receptor gene polymorphisms and bone mineral density in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 765	2.2	2
6	Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
5	Effects of Childhood-onset Systemic Lupus Erythematosus on Academic Achievements and Employment in Adult Life. <i>Journal of Rheumatology</i> , 2021 , 48, 915-923	4.1	1
4	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. <i>Osteoporosis International</i> , 2021 , 32, 1441-1449	5.3	1
3	New developments in systemic lupus erythematosus Rheumatology, 2021, 60, vi21-vi28	3.9	О
2	THU0332 Use and Reasons for Non-Use of Antimalarial Drugs in a Dutch Cohort of Patients with Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A277.3-A278	2.4	
1	Work participation and sick leave in women with systemic lupus erythematosus and matched	2.2	